Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CASH FLOWS

v2.4.1.9
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Operating activities:    
Net loss $ (99)us-gaap_NetIncomeLoss $ (3,887)us-gaap_NetIncomeLoss
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 199us-gaap_DepreciationAndAmortization 236us-gaap_DepreciationAndAmortization
Stock-based compensation 38us-gaap_ShareBasedCompensation 55us-gaap_ShareBasedCompensation
Fair value of warrant liabilities in excess of proceeds from financing 946us-gaap_FairValueAdjustmentOfWarrants   
Change in fair value of derivative liabilities (5,730)us-gaap_DerivativeGainLossOnDerivativeNet (192)us-gaap_DerivativeGainLossOnDerivativeNet
Deferred income tax (52)cocp_DeferredIncomeTax   
Loss on return of escrowed shares 584us-gaap_GainLossOnDispositionOfAssets   
Realized gain on sale of marketable securities (1,359)us-gaap_RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments   
Loss on sale of equipment 6us-gaap_GainLossOnSaleOfPropertyPlantEquipment   
Changes in operating assets and liabilities, net of effects of reverse merger with Biozone Pharmaceuticals, Inc. and the merger with RFS Pharma, LLC:    
Prepaid expenses and other current assets 9us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (1)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Accounts payable and accrued expenses (551)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities 103us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
Net cash used in operating activities (6,009)us-gaap_NetCashProvidedByUsedInOperatingActivities (3,686)us-gaap_NetCashProvidedByUsedInOperatingActivities
Investing activities    
Cash acquired in acquisition of Biozone Pharmaceuticals, Inc. 589us-gaap_CashAcquiredFromAcquisition   
Cash acquired in acquisition of RFS Pharma, Inc. 194cocp_CashAcquiredInAcquisitionOfRfsPharmaInc.   
Purchase of property and equipment (5)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (4)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Long term deposits (3)us-gaap_RepaymentsOfLongTermDebt   
Proceeds from sale of marketable securities 7,900us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities   
Investment in mortgage note receivable (2,626)us-gaap_PaymentsToAcquireMortgageNotesReceivable   
Principal payments received on mortgage note receivable 30cocp_PrincipalPaymentsReceivedOnMortgageNoteReceivable   
Net cash provided by (used in) investing activities 6,079us-gaap_NetCashProvidedByUsedInInvestingActivities (4)us-gaap_NetCashProvidedByUsedInInvestingActivities
Financing activities    
Proceeds from exercise of stock options 116us-gaap_ProceedsFromStockOptionsExercised 7us-gaap_ProceedsFromStockOptionsExercised
Proceeds from issuance of common stock and warrants 2,750us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants   
Net cash provided by financing activities 2,866us-gaap_NetCashProvidedByUsedInFinancingActivities 7us-gaap_NetCashProvidedByUsedInFinancingActivities
Net increase (decrease) in cash and cash equivalents 2,936us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (3,683)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents, beginning of period 1,034us-gaap_CashAndCashEquivalentsAtCarryingValue 4,717us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents, end of period 3,970us-gaap_CashAndCashEquivalentsAtCarryingValue 1,034us-gaap_CashAndCashEquivalentsAtCarryingValue
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Unrealized gain on marketable securities net of tax 236us-gaap_MarketableSecuritiesUnrealizedGainLoss   
Fair value of assets acquired and liabilities assumed in reverse merger with Biozone Pharmaceuticals, Inc.      
Prepaid expenses and other current assets 5cocp_PrepaidExpensesAndOtherCurrentAssetsOne   
Marketable securities 8,811us-gaap_MarketableSecuritiesGainLoss   
Accounts payable and accrued expenses (410)cocp_AccountsPayableAndAccruedExpensesOne   
Derivative liabilities (10,475)us-gaap_LiabilitiesAssumed1   
Fair value of Series A preferred stock issued in acquisition of RFS Pharma, LLC 178,218cocp_FairValueOfSeriesPreferredStockIssuedInAcquisitionOfRfsPharmaLlc   
Fair value of stock options issued in acquisition of RFS Pharma, LLC 6,565cocp_FairValueOfStockOptionsIssuedInAcquisitionOfRfsPharmaLlc   
Fair value of assets acquired and liabilities assumed in acquisition of RFS Pharma, LLC      
In-process research and development 184,966us-gaap_ResearchAndDevelopmentInProcess   
Goodwill 65,195us-gaap_GoodwillAcquiredDuringPeriod   
Deferred tax liabilities (65,195)us-gaap_SupplementalDeferredPurchasePrice   
Prepaid expenses and other current assets 132cocp_PrepaidExpensesAndOtherCurrentAssets  
Accounts payable and accrued expenses (532)cocp_AccountsPayableAndAccruedExpenses  
Property and equipment 14cocp_PropertyAndEquipment   
Other long term assets $ 10cocp_OtherLongTermAssets